Who's who

3 Houston innovators to know this week

Accenture and Plug and Play Tech Center made strategic hires in Houston. Plus, a local expert shares how important electronics recycling is. Courtesy photos

The movers and shakers of the Houston innovation world did a lot of extra moving and shaking last week. This week's Houston innovators to know include two new hires within the ecosystem.

Thomas Rubenak, senior principal at Accenture Ventures

Thomas Rubenak is senior principal of Accenture Ventures. Courtesy of Accenture

Thomas Rubenak has watched Houston's startup scene blossom over his career. Now, as senior principal at Accenture Ventures, he gets to help startups connect with Accenture and its clients.

"It's a win-win-win," Rubenak tells InnovationMap. "The client gets the benefit of having the best of the best and the startups get amazing exposure to companies they might not have been able to get in front of. And, Accenture is happy because it gets to serve the client." Read more about Rubenak and his new gig at Accenture.

Payal Patel, director of corporate relations at Plug and Play

Payal Patel, former director of business development at Station Houston, has joined Plug and Play as director of corporate partnerships. Courtesy of Payal Patel

Plug and Play Tech Center has made its first Houston hire. Payal Patel, who was preciously the director of business development at Station Houston, is now the director of corporate partnerships at Plug and Play.

"As I've gotten to know Plug and Play, what I've been most impressed with is the resources and capabilities they have," Patel says. "They've got great Fortune 500 corporate partners, they work and know the best tech startups all over the world, and they have a strong investment capability. I'm excited that those resources and capabilities are coming to Houston." Read more about the new hire and Plug and Play's plans for Houston.

Ed Wooten, director of ITAD at Smith

Wooten oversees IT asset disposition for Smith. Courtesy of Smith

Ed Wooten is in the business of safe, efficient, and responsible electronics disposal. In a world with cybersecurity threats around every corner, making sure your devices are responsibly disposed of is so important. Wooten wrote a guest article for InnovationMap about some of the lesser-known aspects regarding IT asset disposition.

"I've worked in the technology industry for over 20 years, helping customers across all industries ensure the proper and secure disposal of their equipment," writes Wooten. "I specifically want Houston businesses to be aware of some of the less-obvious facts when it comes to electronics recycling and disposal — and for them to know that trusted, locally based IT asset disposition (ITAD) services are available." Read more of Wooten's piece here.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News